Pentaglobin effect in critically ill patients with COVID-19

INTERVENTION: Intervention 1: Intervention group: Patients received 5 ml/kg body weight / day Pentaglobin (Biotest company, Germany) for 3 consecutive days. Patients also received standard treatment and supportive care (oxygen therapy and Anticoagulant) according to national guideline for COVID‐19. Intervention 2: Control group: Patients will receive lopinavir‐ritonavir (Heterd company, India) at dose of 200/50 mg two tablets BID for 7 days with the standard and supportive care (oxygen therapy and Anticoagulant) according to national guidelines for COVID‐19. CONDITION: COVID‐19 pneumonia. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Death. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record. Need for invasive mechanical ventilation. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record. Supportive treatment with non‐invasive oxygen. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record. SECONDARY OUTCOME: Hospitalization duration. Timepoint: 28 days after admission. Method of measurement: Medical records. Ventilation duration. Timepoint: 7 and 14 days after admission. Method of measurement: Medical record. INCLUSION CRITERIA: Laboratory COVID‐19 confirmed with RT‐PCR who has acute respiratory distress syndrome Severely ill patient Oxygen saturation < 93% Not responding to national protocol after 72 hours Bilateral pulmonary infiltration Signed the consent form